The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: Implications for melanoma progression

European Journal of Dermatology

Volumn 21, Issue 2, 2011, Pages 178-183

  Pepe, Carla Antonella ^a   Ricci, Roberto ^a   Cortelazzi, Chiara ^a   Mori, Giovanni ^a   Zambito, Fabio ^a   Campanini, Nicoletta ^a   Aimi, Francesca ^a   Santoro, Silvia ^a   Lombardi, Mara ^a   Santini, Marcello ^a   de Panfilis, Giuseppe ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Anti melanoma immunity; CD27; FOXP3; Melanoma progression; Regulatory T cells; Tumour infiltrating lymphocytes

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL LABELING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MELANOMA; MORPHOMETRICS; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; SKIN CARCINOGENESIS; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANTIGENS, CD27; DERMATITIS; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 79960802139     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.1240     Document Type: Article

References (48)

1. Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005; 15: 63-9.
2. Yazdi AS, Morstedt K, Puchta U, et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol 2006; 126: 393-8.
3. Clark WH Jr., Elder DE, Guerry 4th. D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893-904.
4. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
5. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188: 1641-50.
6. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cellmediated vitiligo. J Exp Med 2000; 192: 1637-44.
7. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107-18.
8. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 2005; 174: 2661-70.
9. De Panfilis G, Campanini N, Santini M, et al. Phase-and stagerelated proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 2008; 128: 676-84.
10. Fontenot GD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-7.
11. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 209-26.
12. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445: 936-40.
13. Tashman S, Anderst W, Kolowich P, Havstad S, Arnoczky S. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 22: 931-5.
14. Sadlon TJ, Wilkinson BG, Pederson S, et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol 2010; 185: 1071-81.
15. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007; 37: 21-3.
16. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103: 6659-64.
17. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116: 1713-22.
18. Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 2007; 30: 294-302.
19. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 293: 2087-92.
20. Agarwal A, Newell KA. The role of positive costimulatory molecules in transplantation and tolerance. Curr Opin Org Transplant 2008; 13: 366-72.
21. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev 2009; 9: 271-85.
22. Yamaura K, Boenisch O, Watanabe T, et al. Differential requirement of CD27 costimulatory signaling for naïve versus alloantigen-primed effector/memory CD8+ T cells. Am J Transplant 2010; 10: 1210-20.
23. Duggleby RC, Shaw TN, Jarvis LB, Kaur G, Gaston JS. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. Immunology 2007; 121: 129-39.
24. Koenen HJ, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005; 174: 7573-83.
25. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201: 1793-803.
26. Mack DG, Lanham AM, Palmer BE, Maier LA, Fontenot AP. CD27 expression on CD4+ T cells differentiates effector from regulatory T cell subsets in the lung. J Immunol 2009; 182: 7317-24.
27. Arens R, Tesselaar K, Baars PA, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion. Immunity 2001; 15: 801-12.
28. Yamada S, Shinozaki K, Agematsu K. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol 2002; 130: 424-30.
29. Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 2008; 29: 934-46.
30. Glouchkova L, Ackermann B, Zibert A, et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukaemia. J Immunol 2009; 182: 718-25.
31. Keller AM, Xiao Y, Peperzak V, Naik SH, Borst J. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Blood 2009; 113: 5167-75.
32. + T cells. J Exp Med 1997; 186: 1407-18.
33. -human T cells. J Immunol 2000; 165: 1910-7.
34. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today 1999; 20: 177-80.
35. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379-85.
36. Tomiyama H, Takata H, Matsuda T, Takiguchi M. Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. Eur J Immunol 2004; 34: 999-1010.
37. Takata H, Takiguchi M. Three memory subsets of human CD8+ T cells differently expressing three cytolytic effector molecules. J Immunol 2006; 177: 4330-40.
38. Koenen HJ, Smeets RL, Vink PM, et al. Human CD25 high-Foxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-52.
39. Vukmanovic-Stejic M, Agius E, Booth N, et al. The kinetics of CD4+ Foxp3+ T cell accumulation during a human cutaneous antigenspecific memory response in vivo. J Clin Invest 2008; 118: 3639-50.
40. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112: 4953-60.
41. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-44.
42. Li Y, Liu S, Hernandez J, et al. Mart-1-specific melanoma tumorinfiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184: 452-65.
43. Ryan MC, Kostner H, Gordon KA, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibodydrug conjugate SGN-75. Br J Cancer 2010; 103: 676-84.
44. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 667-704.
45. + T cells producing IL-17. J Immunol 2009; 182: 1794-8.
46. Battaglia A, Buzzonetti A, Baranello C, et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumor draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009; 58: 1363-73.
47. + regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res 2005; 65: 8479-86.
48. Nikolova M, Lelievre JD, Carriere M, et al. Regulatory T cells modulate differentially the maturation and apoptosis of human CD8-T cell subsets. Blood 2009; 113: 4556-65.